Rnam Expression and Dna Methylation of Dkk2 Gene in Colorectal Câncer

2023

Preprint

Background: Clinicopathological features are used for detection of diseases. Early detection of cancer can be significance for understanding the behavior of disease. Results: We developed a tool to observe stomach adenocarcinoma in reference of blood-lipid profile. Background of the tool is based on the study made on RNAseq expression analysis of stomach adenocarcinoma. Raw data for study was collected as gene-expression profile from population of cancer-vs-normal. A series of studies performed including: differential gene expression analysis, plasma proteome mapping, extraction of gene-signature enriched with LSTM system model, AI-guided simulation of systems model of gene network, and AI-guided mapping with blood lipid profile to develop R-Shiny web-application. Conclusion: EarlyDetect, is freely available at https://csir-icmr.shinyapps.io/EarlyDetect/. The tool can be utilized for (i) virtual observation of impact of different combinations of lipid profile in cancer progression; (ii) early detection of cancer state for new comer patients.

Section: Introductionmentioning

confidence: 99%

EarlyDetect: Development of tool for early detection of stomach adenocarcinoma based on blood-lipid profile as clinicopathological feature

2023

Preprint

“…Transcriptome RNA expressions are also used for identification of targetable disease regulatory networks for disease diagnosis (Gaffo et.al., 2021). RNA based studies are well known with hepatocellular carcinoma (Chen et.al., 2018), colorectal cancer (Mamelli et.al., 2021), pathway detection (Wu et.al., 2021), prostate tumor (Xia et.al., 2018), and breast cancer (Liu et.al., 2021) etc. RNA expression profile/signature are also utilised for early diagnosis (Zheng et.al., 2019; Liu et.al., 2021).…”

Section: Introductionmentioning

confidence: 99%

Triggering blood-lipid-profile by immunomodulatory and antimicrobial molecules for cross-evaluation of early detection of cancer

2023

Preprint

BackgroundAl-guided mapping establishes relationship between gene-signature and phenotype. Since, Immunomodulatory & antimicrobial molecules, both show anticancer as well as their relation with lipid; therefore, can be further used for cross-validation or enrichment analysis for early detection of cancer. Considering the information, a study was performed on the influence of Immunomodulatory and antimicrobial molecules on blood lipid profile at the early stage of cancer.Materials and MethodPresent study established a relationship between small molecule-vs-genotype to phenotype. Genotypic features extracted through RNAseq analysis for stomach adenocarcinoma, which was further mapped with blood lipid profile. RNA-seq expression, from a population, was collected as gene expression profile of transcriptome. Gene signature was identified through in-house processing. Blood lipid profile was as: Total Cholesterol, LDL Cholesterol, HDL Cholesterol, Triglycerides, Non-HDL-C, and TG to HDL ratio.ResultsTo evaluate the Immunomodulatory and antimicrobial molecules for anticancer activity in terms of their influence on blood lipid-profile, computational models were established for developing relationships between small molecules-vs-genotype. Immunomodulatory and antimicrobial activity showed significant impact on genotypic expression at cancerous conditions.ConclusionIt was concluded that usage of Immunomodulatory small molecules & antibiotics showed their impact on blood lipid profile. These results may support cross-checking the possibility of cancer during the early detection of cancer. Furthermore, suggested the use of immunomodulatory and antimicrobial small molecules for cross evaluation of early disease prediction of different cancer types.

“…Due to population discrimination capacity of RNA biomarkers, transcriptome sequencing is used in diagnosis of disorders (Akula et.al., 2021). RNA based studies are also known for hepatocellular carcinoma (Chen et.al., 2018), colorectal cancer (Mamelli et.al., 2021), pathway detection (Wu et.al., 2021), prostate tumor (Xia et.al., 2018), and breast cancer (Liu et.al., 2021) etc. More refined, RNA expression profiles are also used for early diagnosis of disease.…”

Section: Introductionmentioning

confidence: 99%

Blood lipid density decreases at the early-stage of stomach adenocarcinoma

2023

Preprint

BackgroundInduction of cancer creates many molecular to physiological changes in the human body. Observation of these variations between normal & diseased conditions become the basis of disease diagnosis. Present study analyzed blood lipid profile, relative to changes in genotype, at the early stage of stomach adenocarcinoma.Materials and MethodPresent study was based on establishment of relationship between genotype to phenotype. Genotypic features were collected through RNAseq analysis, which was further mapped with phenotypic expression in the form of blood lipid profile.ResultsTo observe the significance difference between phenotypic expressions of normal and cancerous condition, gene signatures from multiple sources of studies were mapped with blood lipid profile including: Total Cholesterol, LDL Cholesterol, HDL Cholesterol, Triglycerides, Non-HDL-C, and TG to HDL ratio. Significance difference found between phenotypic expression of normal and cancerous condition.ConclusionThrough multi-signature-based population observation, it was found that blood-lipid density decreases at the early-stage of stomach adenocarcinoma. Further, blood-lipid profile can be used for early disease prediction of stomach adenocarcinoma as well as other cancer types.